OVID

2.52

3.08% -0.08

Dopo l'orario di chiusura: 2.47 -0.05 -1.98%

Ovid Therapeutics Inc (OVID)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$2.60

Aprire:

$2.59

Volume 24 ore:

1.39M

Relative Volume:

0.51

Capitalizzazione di mercato:

$470.33M

Reddito:

$7.12M

Utile/perdita netta:

$-24.17M

Rapporto P/E:

-10.35

EPS:

-0.2434

Flusso di cassa netto:

$-41.95M

1 W Prestazione:

-6.32%

1M Prestazione:

+10.53%

6M Prestazione:

+50.90%

1 anno Prestazione:

+501.43%

Intervallo 1D:

$2.42

$2.60

Intervallo di 1 settimana:

$2.42

$2.82

Portata 52W:

$0.36

$3.105

Ovid Therapeutics Inc Stock (OVID) Company Profile

Nome

Ovid Therapeutics Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

212-776-4381

Indirizzo

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Dipendente

Cinguettio

@OvidRx

Prossima data di guadagno

2026-08-12

Ultimi documenti SEC

OVID's Discussions on Twitter

Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OVID Ovid Therapeutics Inc	2.52	470.33M	7.12M	-24.17M	-41.95M	-0.2434
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-11	Iniziato	Roth Capital	Buy
2025-11-17	Iniziato	Leerink Partners	Outperform
2025-10-09	Iniziato	Oppenheimer	Outperform
2025-08-08	Ripresa	B. Riley Securities	Buy
2024-06-18	Downgrade	Oppenheimer	Outperform → Perform
2024-04-30	Iniziato	B. Riley Securities	Buy
2024-04-29	Iniziato	H.C. Wainwright	Buy
2024-04-05	Iniziato	Wedbush	Outperform
2023-12-21	Iniziato	BTIG Research	Buy
2023-10-13	Iniziato	Oppenheimer	Outperform
2021-04-20	Downgrade	Cantor Fitzgerald	Buy → Neutral
2021-03-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-12-02	Downgrade	Citigroup	Buy → Neutral
2020-12-02	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-04	Iniziato	RBC Capital Mkts	Outperform
2018-04-20	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Ovid Therapeutics Inc Borsa (OVID) Ultime notizie

Jul 09, 2026

Ovid Therapeutics appoints Charles Carter as new CFO - The Globe and Mail

Jul 09, 2026

Jul 08, 2026

Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028 - Stock Titan

Jul 08, 2026

Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options - Stock Titan

Jul 08, 2026

Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID - Moomoo

Jul 08, 2026

PR News | On the Move: Ovid Therapeutics Hires Fort as CSOWed., Jul. 8, 2026 - O'Dwyer's PR

Jul 08, 2026

Ovid Therapeutics names new chief business officer - Investing.com

Jul 08, 2026

Ovid Therapeutics: Victoria Fort Promoted to Chief Strategy Officer >OVID - Moomoo

Jul 08, 2026

Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed - Stock Titan

Jul 08, 2026

Ovid Therapeutics names new chief business officer By Investing.com - Investing.com Canada

Jul 08, 2026

Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo

Jul 08, 2026

New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant - Stock Titan

Jul 08, 2026

Ovid adds new business, finance and R&D leaders - Stock Titan

Jul 08, 2026

Jul 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 07, 2026

Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha

Jul 07, 2026

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions - Seeking Alpha

Jul 07, 2026

Jul 03, 2026

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth - Sahm

Jul 03, 2026

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026